Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6853676 | 1.00 | AAK1 (0.43) | AAK1MTNR1AMTNR1BTRPA1CYP1A2 | |
| SCHEMBL6855122 | 0.86 | AAK1 (0.47) | AAK1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6854987 | 0.86 | AAK1 (0.47) | AAK1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL14005405 | 0.85 | SCN9A (0.39) | AAK1MTNR1AMTNR1BTRPA1 | |
| SCHEMBL6855273 | 0.83 | TRPA1 (0.36) | AAK1MTNR1AMTNR1BTRPA1 | |
| SCHEMBL6855278 | 0.83 | TRPA1 (0.36) | AAK1MTNR1AMTNR1BTRPA1 | |
| SCHEMBL6853437 | 0.82 | CTSK (0.42) | AAK1 | |
| SCHEMBL6853436 | 0.82 | CTSK (0.42) | AAK1 | |
| SCHEMBL25075129 | 0.81 | MTNR1A (0.51) | AAK1MTNR1AMTNR1B | |
| SCHEMBL6854852 | 0.81 | AAK1 (0.37) | AAK1TRPA1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023020479-A1 | PARP7 INHIBITOR AND APPLICATION THEREOF | 重庆华森制药股份有限公司 | 2023-02-23 | — | — | WO | disclosed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | AAK1 149/4885MTNR1A 4425/4885MTNR1B 4077/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | AAK1 149/4885MTNR1A 4425/4885MTNR1B 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.